SCHEDULE: Adage Capital Reduces Stake in Amylyx Pharmaceuticals

Sentiment:

Beneficial Ownership Amendment 12 February 2026 9:09 AM

📋All filings for Amylyx Pharmaceuticals, INC

Adage Capital Management and its principals have reduced their beneficial ownership in Amylyx Pharmaceuticals, Inc. to 2.53%.

Worse than expectedAdage Capital Management, L.P. and its principals have reduced their beneficial ownership in Amylyx Pharmaceuticals, Inc. to 2.53%, down from a previous stake that would have been above the 5% threshold, as indicated by this being Amendment No. 3 to their Schedule 13G filing.

Summary

Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross (collectively, the "Reporting Persons") have filed an Amendment No. 3 to their Schedule 13G.
The Reporting Persons collectively beneficially own 2,777,055 shares of Amylyx Pharmaceuticals, Inc. Common Stock.
This ownership represents 2.53% of the outstanding Common Stock, calculated based on 109,819,569 shares outstanding as of October 27, 2025.
The filing indicates a reduction in beneficial ownership to below the 5% threshold, as this is an amendment to a previous Schedule 13G filing.
Adage Capital Management, L.P. is an investment adviser, and Robert Atchinson and Phillip Gross are individuals associated with the firm.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal, as a significant institutional investor has reduced its stake below the 5% reporting threshold, potentially indicating a decrease in conviction or a reallocation of capital.

Positives

Negatives

The filing indicates a reduction in beneficial ownership by Adage Capital Management, L.P. and its principals to 2.53%, implying they have sold a portion of their stake to fall below the 5% reporting threshold.

Risks

Future Outlook

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially reductions below key reporting thresholds, are closely watched by the market as they can signal a shift in investor confidence or portfolio strategy. Such movements can influence broader market sentiment towards the issuer.

Stakeholder Impact

Shareholders may interpret the reduction in institutional ownership as a negative signal, potentially impacting investor sentiment and share price.

Key Dates

Date	Description
2025-10-27	Date as of which 109,819,569 shares of Common Stock were outstanding, used for percentage calculation, as reported in the Company's Form 10-Q.
2025-12-31	Date of event which requires filing of this statement (reporting period end).
2026-02-12	Filing date of the Schedule 13G Amendment No. 3.

Recommendation

sell

Adage Capital Management, L.P. and its principals have reduced their beneficial ownership in Amylyx Pharmaceuticals, Inc. to 2.53%, implying a significant reduction from a prior stake that was above the 5% threshold. This action by a major institutional investor suggests a lack of conviction or a strategic divestment, which could be interpreted as a negative signal for the stock.

Keywords

Amylyx Pharmaceuticals, Adage Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.